Article Impact Level: HIGH Data Quality: STRONG Summary of British Journal of Clinical Pharmacology https://doi.org/10.1002/bcp.70559 Dr. Lucy Galloway et al.
Points
- The CERSI-PGx has published new clinical guidelines in the British Journal of Clinical Pharmacology to standardize HLA genotype testing for carbamazepine and its related anti-seizure compounds.
- Specific HLA gene variants are known to significantly increase the risk of unpredictable and severe immune-mediated cutaneous reactions that are independent of the drug dosage administered.
- This guideline provides practical recommendations for clinicians on patient testing eligibility, specific variant identification, and appropriate actions to take based on a patient’s detected genetic risk profile.
- Researchers emphasized the importance of considering structural cross-reactivity between drugs to ensure that alternative medications are safe for individuals who carry a high-risk HLA allele.
- The implementation of these pharmacogenetic screening protocols aligns with national healthcare plans to modernize the health system by utilizing precision medicine to prevent adverse drug reactions.
Summary
This study presents a specialized prescribing guideline developed by the UK Center of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) to mitigate immune-mediated hypersensitivity reactions associated with carbamazepine, oxcarbazepine, and eslicarbazepine. While these agents are standard therapies for epilepsy, bipolar disorder, and trigeminal neuralgia, they are frequently implicated in idiosyncratic, non-dosage-dependent cutaneous adverse reactions. The research confirms that specific human leukocyte antigen (HLA) gene variants significantly predispose patients to severe, potentially life-threatening reactions, necessitating a standardized genomic screening protocol prior to drug initiation.
The CERSI-PGx guideline diverges from broad international standards by providing high-resolution clinical pathways tailored to the NHS healthcare infrastructure. It establishes clear criteria for patient eligibility, specific HLA alleles for testing, and optimized turnaround times to prevent treatment delays. Furthermore, the analysis addresses the critical issue of structural cross-reactivity between carbamazepine and its analogues, offering actionable alternative prescribing strategies based on detected risk alleles. By integrating health economic considerations and identifying existing evidence gaps, the study provides a pragmatic framework for the national rollout of pharmacogenetic testing as outlined in long-term healthcare strategic plans.
Ultimately, the implementation of these recommendations aims to transform the safety profile of aromatic anti-seizure medications through precision medicine. The researchers emphasize that the presence of risk variants should preclude the use of the primary drug and its structural relatives to avoid multisystem organ involvement, including hepatic dysfunction. This clinical focus ensures that practitioners can navigate the transition from genotype results to prescription choices with confidence. Future research priorities identified in the study will focus on refining these pathways to include diverse ethnic populations and expanding the repertoire of alternative, non-cross-reactive compounds for high-risk individuals.
Link to the article: https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70559
References
Galloway, L., Dello Russo, C., Bass, N., Bramon, E., Cross, H., Curley, N., Curran, S., Davies, H., De Villiers, J., Evans, W., Frank, B., Groves, A., Hayward, J., Higham, J., Hughes, D. A., Kyaw, S. S., Marson, A. G., McLellan, A., Mensah, S., … Pirmohamed, M. (2026). hla genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the uk centre of excellence in regulatory science and innovation in pharmacogenomics(Cersi‐pgx). British Journal of Clinical Pharmacology, bcp.70559. https://doi.org/10.1002/bcp.70559
